A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
March 2020 represented the 10th anniversary of the US biosimilars framework, marking a decade since the then-US president Barack Obama signed into law the Biologics Price Competition and Innovation Act as part of the Affordable Care Act.
However, it is only recently that the US has started to see the market edge toward maturity, in the form...